Long-Term Use of Proton Pump Inhibitors in Cancer Patients: An Opinion Paper
Abstract
:Simple Summary
Abstract
1. Introduction
2. Systemic Toxicity Linked to Long-Term PPI Use with a Possible Impact in Cancer Patients
2.1. Dementia
2.2. Bone Fractures
2.3. Renal Toxicities
2.4. Enteric Infections
2.5. Micronutrient Deficiencies
3. PPIs and Oncologic Treatment Efficacy
3.1. PPIs and Tyrosine Kinase Inhibitors (TKIs)
3.2. PPIs and Other Anticancer Treatments
3.3. PPIs and Immunotherapy
3.4. PPIs and Chemotherapeutic Agents
4. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Vaezi, M.F.; Yang, Y.X.; Howden, C.W. Complications of Proton Pump Inhibitor Therapy. Gastroenterology 2017, 153, 35–48. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Forgacs, I.; Loganayagam, A. Overprescribing proton pump inhibitors. BMJ 2008, 336, 2–3. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lodato, F.; Poluzzi, E.; Raschi, E.; Piccinni, C.; Koci, A.; Olivelli, V.; Napoli, C.; Corvalli, G.; Nalon, E.; De Ponti, F.; et al. Appropriateness of Proton Pump Inhibitor (PPI) prescription in patients admitted to hospital: Attitudes of general practitioners and hospital physicians in Italy. Eur. J. Intern. Med. 2016, 30, 31–36. [Google Scholar] [CrossRef]
- Ekman, L.; Hansson, E.; Havu, N.; Carlsson, E.; Lundberg, C. Toxicological studies on omeprazole. Scand. J. Gastroenterol. Suppl. 1985, 108, 53–69. [Google Scholar] [PubMed]
- Savarino, V.; Marabotto, E.; Furnari, M.; Zingone, F.; Zentilin, P.; Savarino, E. Latest insights into the hot question of proton pump inhibitor safety—A narrative review. Dig. Liver Dis. 2020, 52, 842–852. [Google Scholar] [CrossRef]
- Raoul, J.L.; Guerin-Charbonnel, C.; Edeline, J.; Simmet, V.; Gilabert, M.; Frenel, J.S. Prevalence of Proton Pump Inhibitor Use Among Patients With Cancer. JAMA Netw. Open 2021, 4, e2113739. [Google Scholar] [CrossRef]
- Weersma, R.K.; Zhernakova, A.; Fu, J. Interaction between drugs and the gut microbiome. Gut 2020, 69, 1510–1519. [Google Scholar] [CrossRef]
- Tvingsholm, S.A.; Dehlendorff, C.; Osterlind, K.; Friis, S.; Jaattela, M. Proton pump inhibitor use and cancer mortality. Int. J. Cancer 2018, 143, 1315–1326. [Google Scholar] [CrossRef] [Green Version]
- Wang, X.; Liu, Q.; Halfdanarson, O.O.; Zoega, H.; Sadr-Azodi, O.; Engstrand, L.; Fall, K.; Brusselaers, N. Proton pump inhibitors and survival in patients with colorectal cancer: A Swedish population-based cohort study. Br. J. Cancer 2021, 125, 893–900. [Google Scholar] [CrossRef]
- Raoul, J.L.; Edeline, J.; Gilabert, M.; Senellart, H.; Frenel, J.S. Proton pump inhibitors and cancers: A hazardous association? Bull. Cancer 2020, 107, 458–464. [Google Scholar] [CrossRef]
- Badiola, N.; Alcalde, V.; Pujol, A.; Munter, L.M.; Multhaup, G.; Lleo, A.; Coma, M.; Soler-Lopez, M.; Aloy, P. The proton-pump inhibitor lansoprazole enhances amyloid beta production. PLoS ONE 2013, 8, e58837. [Google Scholar]
- Gomm, W.; von Holt, K.; Thome, F.; Broich, K.; Maier, W.; Fink, A.; Doblhammer, G.; Haenisch, B. Association of Proton Pump Inhibitors with Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis. JAMA Neurol. 2016, 73, 410–416. [Google Scholar] [CrossRef] [PubMed]
- Hill, A.B. The Environment and Disease: Association or Causation? Proc. R. Soc. Med. 1965, 58, 295–300. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- van der Hoorn, M.M.C.; Tett, S.E.; de Vries, O.J.; Dobson, A.J.; Peeters, G. The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study. Bone 2015, 81, 675–682. [Google Scholar] [CrossRef] [Green Version]
- Freedberg, D.E.; Kim, L.S.; Yang, Y.X. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. Gastroenterology 2017, 152, 706–715. [Google Scholar] [CrossRef]
- Andersen, B.N.; Johansen, P.B.; Abrahamsen, B. Proton pump inhibitors and osteoporosis. Curr. Opin. Rheumatol. 2016, 28, 420–425. [Google Scholar] [CrossRef]
- Coleman, R.; Body, J.J.; Aapro, M.; Hadji, P.; Herrstedt, J.; Group, E.G.W. Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann. Oncol. 2014, 25 (Suppl. S3), iii124–iii137. [Google Scholar] [CrossRef]
- Lazarus, B.; Chen, Y.; Wilson, F.P.; Sang, Y.; Chang, A.R.; Coresh, J.; Grams, M.E. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease. JAMA Intern. Med. 2016, 176, 238–246. [Google Scholar] [CrossRef] [Green Version]
- Giusti, S.; Lin, Y.; Sogbetun, F.; Nakhoul, N.; Liu, S.; Shi, L.; Batuman, V. The Effect of Proton Pump Inhibitor Use on the Course of Kidney Function in Patients with Chronic Kidney Disease Stages G3a to G4. Am. J. Med. Sci. 2021, 362, 453–461. [Google Scholar] [CrossRef]
- Hall, R.K.; Blumenthal, J.B.; Doerfler, R.M.; Chen, J.; Diamantidis, C.J.; Jaar, B.G.; Kusek, J.W.; Kallem, K.; Leonard, M.B.; Navaneethan, S.D.; et al. Risk of Potentially Inappropriate Medications in Adults with CKD: Findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am. J. Kidney Dis. 2021, 78, 837–845. [Google Scholar] [CrossRef]
- Imhann, F.; Bonder, M.J.; Vich Vila, A.; Fu, J.; Mujagic, Z.; Vork, L.; Tigchelaar, E.F.; Jankipersading, S.A.; Cenit, M.C.; Harmsen, H.J.; et al. Proton pump inhibitors affect the gut microbiome. Gut 2016, 65, 740–748. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Laheij, R.J.; Sturkenboom, M.C.; Hassing, R.J.; Dieleman, J.; Stricker, B.H.; Jansen, J.B. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004, 292, 1955–1960. [Google Scholar] [CrossRef] [PubMed]
- Jensen, R.T. Consequences of long-term proton pump blockade: Insights from studies of patients with gastrinomas. Basic Clin. Pharmacol. Toxicol. 2006, 98, 4–19. [Google Scholar] [CrossRef] [PubMed]
- Stewart, C.A.; Termanini, B.; Sutliff, V.E.; Serrano, J.; Yu, F.; Gibril, F.; Jensen, R.T. Iron absorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy. Aliment. Pharmacol. Ther. 1998, 12, 83–98. [Google Scholar] [CrossRef]
- Vanclooster, A.; van Deursen, C.; Jaspers, R.; Cassiman, D.; Koek, G. Proton Pump Inhibitors Decrease Phlebotomy Need in HFE Hemochromatosis: Double-Blind Randomized Placebo-Controlled Trial. Gastroenterology 2017, 153, 678–680.e2. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ajmera, A.V.; Shastri, G.S.; Gajera, M.J.; Judge, T.A. Suboptimal response to ferrous sulfate in iron-deficient patients taking omeprazole. Am. J. Ther. 2012, 19, 185–189. [Google Scholar] [CrossRef] [PubMed]
- Cheungpasitporn, W.; Thongprayoon, C.; Kittanamongkolchai, W.; Srivali, N.; Edmonds, P.J.; Ungprasert, P.; O’Corragain, O.A.; Korpaisarn, S.B.; Erickson, S. Proton pump inhibitors linked to hypomagnesemia: A systematic review and meta-analysis of observational studies. Ren. Fail. 2015, 37, 1237–1241. [Google Scholar] [CrossRef] [Green Version]
- Recart, D.A.; Ferraris, A.; Petriglieri, C.I.; Alonso Serena, M.; Bonella, M.B.; Posadas-Martinez, M.L. Prevalence and risk factors of long-term proton pump inhibitors-associated hypomagnesemia: A cross-sectional study in hospitalized patients. Intern. Emerg. Med. 2021, 16, 711–717. [Google Scholar] [CrossRef]
- van Leeuwen, R.W.F.; Jansman, F.G.A.; Hunfeld, N.G.; Peric, R.; Reyners, A.K.L.; Imholz, A.L.T.; Brouwers, J.; Aerts, J.G.; van Gelder, T.; Mathijssen, R.H.J. Tyrosine Kinase Inhibitors and Proton Pump Inhibitors: An Evaluation of Treatment Options. Clin. Pharmacokinet. 2017, 56, 683–688. [Google Scholar] [CrossRef]
- Budha, N.R.; Frymoyer, A.; Smelick, G.S.; Jin, J.Y.; Yago, M.R.; Dresser, M.J.; Holden, S.N.; Benet, L.Z.; Ware, J.A. Drug absorption interactions between oral targeted anticancer agents and PPIs: Is pH-dependent solubility the Achilles heel of targeted therapy? Clin. Pharmacol. Ther. 2012, 92, 203–213. [Google Scholar] [CrossRef]
- van Leeuwen, R.W.; van Gelder, T.; Mathijssen, R.H.; Jansman, F.G. Drug-drug interactions with tyrosine-kinase inhibitors: A clinical perspective. Lancet Oncol. 2014, 15, e315–e326. [Google Scholar] [CrossRef]
- Indini, A.; Petrelli, F.; Tomasello, G.; Rijavec, E.; Facciorusso, A.; Grossi, F.; Ghidini, M. Impact of Use of Gastric-Acid Suppressants and Oral Anti-Cancer Agents on Survival Outcomes: A Systematic Review and Meta-Analysis. Cancers 2020, 12, 998. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Routy, B.; Le Chatelier, E.; Derosa, L.; Duong, C.P.M.; Alou, M.T.; Daillere, R.; Fluckiger, A.; Messaoudene, M.; Raubert, C.; Roberti, M.P.; et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 2018, 359, 91–97. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Parsad, S.; Ratain, M.J. Drug-Drug Interactions With Oral Antineoplastic Agents. JAMA Oncol. 2017, 3, 736–738. [Google Scholar] [CrossRef]
- Uchiyama, A.A.T.; Silva, P.; Lopes, M.S.M.; Yen, C.T.; Ricardo, E.D.; Mutao, T.; Pimenta, J.R.; Machado, L.M.; Shimba, D.S.; Peixoto, R.D. Proton Pump Inhibitors and Oncologic Treatment Efficacy: A Practical Review of the Literature for Oncologists. Curr. Oncol. 2021, 28, 783–799. [Google Scholar] [CrossRef]
- Peters, S.; Zimmermann, S.; Adjei, A.A. Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug-drug interactions. Cancer Treat. Rev. 2014, 40, 917–926. [Google Scholar] [CrossRef] [Green Version]
- Veerman, G.D.M.; Hussaarts, K.; Peric, R.; Oomen-de Hoop, E.; Landa, K.D.; van der Leest, C.H.; Broerse, S.D. Influence of Cow’s Milk and Esomeprazole on the Absorption of Erlotinib: A Randomized, Crossover Pharmacokinetic Study in Lung Cancer Patients. Clin. Pharmacokinet. 2021, 60, 69–77. [Google Scholar] [CrossRef]
- Chu, M.P.; Ghosh, S.; Chambers, C.R.; Basappa, N.; Butts, C.A.; Chu, Q.; Fenton, D.; Joy, A.A.; Sangha, R.; Smylie, M.; et al. Gastric Acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer. Clin. Lung Cancer 2015, 16, 33–39. [Google Scholar] [CrossRef]
- Fang, Y.H.; Yang, Y.H.; Hsieh, M.J.; Hung, M.S.; Lin, Y.C. Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment—A nationwide population-based study. Cancer Manag. Res. 2019, 11, 8539–8546. [Google Scholar] [CrossRef] [Green Version]
- Sharma, M.; Holmes, H.M.; Mehta, H.B.; Chen, H.; Aparasu, R.R.; Shih, Y.T.; Giordano, S.H.; Johnson, M.L. The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: Prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer. Cancer 2019, 125, 1155–1162. [Google Scholar] [CrossRef]
- Lalani, A.A.; McKay, R.R.; Lin, X.; Simantov, R.; Kaymakcalan, M.D.; Choueiri, T.K. Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma. Clin. Genitourin. Cancer 2017, 15, 724–732. [Google Scholar] [CrossRef] [PubMed]
- Boegemann, M.; Schlack, K.; Rink, M.; Bernhardt, S.; Moran, M.; Hubbe, M.; Bergmann, L.; Schmid, M.; Strauss, A. Effect of comorbidities/comedications on sunitinib outcomes for metastatic renal cell carcinoma: The STAR-TOR registry. Future Oncol. 2020, 16, 2939–2948. [Google Scholar] [CrossRef]
- Vishwanathan, K.; Dickinson, P.A.; Bui, K.; Cassier, P.A.; Greystoke, A.; Lisbon, E.; Moreno, V.; So, K.; Thomas, K.; Weilert, D.; et al. The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients with Non-Small-Cell Lung Cancer and in Healthy Volunteers. J. Clin. Pharmacol. 2018, 58, 474–484. [Google Scholar] [CrossRef] [PubMed]
- Mir, O.; Touati, N.; Lia, M.; Litiere, S.; Le Cesne, A.; Sleijfer, S.; Blay, J.Y.; Leahy, M.; Young, R.; Mathijssen, R.H.J.; et al. Impact of Concomitant Administration of Gastric Acid-Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials. Clin. Cancer Res. 2019, 25, 1479–1485. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- de Man, F.M.; Hussaarts, K.; de With, M.; Oomen-de Hoop, E.; de Bruijn, P.; van Halteren, H.K.; van der Burg-de Graauw, N.; Eskens, F.; van Gelder, T.; van Leeuwen, R.W.F.; et al. Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic Study. Clin. Pharmacol. Ther. 2019, 105, 1456–1461. [Google Scholar] [CrossRef] [PubMed]
- Hussaarts, K.; Veerman, G.D.M.; Jansman, F.G.A.; van Gelder, T.; Mathijssen, R.H.J.; van Leeuwen, R.W.F. Clinically relevant drug interactions with multikinase inhibitors: A review. Ther Adv. Med. Oncol. 2019, 11, 1758835918818347. [Google Scholar] [CrossRef]
- Bezabeh, S.; Mackey, A.C.; Kluetz, P.; Jappar, D.; Korvick, J. Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors. Oncologist 2012, 17, 550–554. [Google Scholar] [CrossRef] [Green Version]
- Wu, C.Y.; Ho, H.J.; Wu, C.Y.; Chen, Y.J.; Lee, T.Y.; Hsu, Y.C.; Lin, J.T. Association between proton pump inhibitor use and mortality in patients with hepatocellular carcinoma receiving tyrosine kinase inhibitor. Gut 2020, 70, 1598–1599. [Google Scholar] [CrossRef]
- Razak, R.A.; Fletcher, P.; Kunene, V.; Ma, Y.T. Association of Gastric Acid Suppression and Sorafenib Efficacy in Advanced Hepatocellular Carcinoma. J. Clin. Gastroenterol. 2020, 55, 169–173. [Google Scholar] [CrossRef]
- Ruanglertboon, W.; Sorich, M.J.; Logan, J.M.; Rowland, A.; Hopkins, A.M. The effect of proton pump inhibitors on survival outcomes in advanced hepatocellular carcinoma treated with sorafenib. J. Cancer Res. Clin. Oncol. 2020, 146, 2693–2697. [Google Scholar] [CrossRef]
- Li, L.; Xiang, Y.X.; Yang, G.P.; Zhang, X.F.; Yang, X.Y.; Yang, S.; Huang, J. Pharmacokinetic effects of proton pump inhibitors on the novel PARP inhibitor fluzoparib: A single-arm, fixed-sequence trial in male healthy volunteers. Investig. New Drugs 2021, 39, 796–802. [Google Scholar] [CrossRef] [PubMed]
- Sun, W.; Klamerus, K.J.; Yuhas, L.M.; Pawlak, S.; Plotka, A.; O’Gorman, M.; Kirkovsky, L.; Kosa, M.; Wang, D. Impact of Acid-Reducing Agents on the Pharmacokinetics of Palbociclib, a Weak Base With pH-Dependent Solubility, With Different Food Intake Conditions. Clin. Pharmacol. Drug Dev. 2017, 6, 614–626. [Google Scholar] [CrossRef] [PubMed]
- Del Re, M.; Omarini, C.; Diodati, L.; Palleschi, M.; Meattini, I.; Crucitta, S.; Lorenzini, G.; Isca, C.; Fontana, A.; Livi, L.; et al. Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. ESMO Open. 2021, 6, 100231. [Google Scholar] [CrossRef]
- Gibbons, J.A.; de Vries, M.; Krauwinkel, W.; Ohtsu, Y.; Noukens, J.; van der Walt, J.S.; Mol, R.; Mordenti, J.; Ouatas, T. Pharmacokinetic Drug Interaction Studies with Enzalutamide. Clin. Pharmacokinet. 2015, 54, 1057–1069. [Google Scholar] [CrossRef] [Green Version]
- Derosa, L.; Hellmann, M.D.; Spaziano, M.; Halpenny, D.; Fidelle, M.; Rizvi, H.; Long, N.; Plodkowski, A.J.; Arbour, K.C.; Chaft, J.E.; et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann. Oncol. 2018, 29, 1437–1444. [Google Scholar] [CrossRef]
- Gopalakrishnan, V.; Spencer, C.N.; Nezi, L.; Reuben, A.; Andrews, M.C.; Karpinets, T.V.; Prieto, P.A.; Vincente, D.; Hoffman, K.; Wei, S.C.; et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 2018, 359, 97–103. [Google Scholar] [CrossRef] [Green Version]
- Homicsko, K.; Richtig, G.; Tuchmann, F.; Tsourti, Z.; Hanahan, D.; Coukos, G.; Wind-Rotolo, M.; Richtig, E.; Zygoura, P.; Holler, C.; et al. Proton pump inhibitors negatively impact survival of PD-1 inhibitor based therapies in metastatic melanoma patients. Ann. Oncol. 2018, 29, x40. [Google Scholar] [CrossRef]
- Chalabi, M.; Cardona, A.; Nagarkar, D.R.; Dhawahir Scala, A.; Gandara, D.R.; Rittmeyer, A.; Albert, M.L.; Powles, T.; Kok, M.; Herrera, F.G.; et al. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: Pooled post hoc analyses of the OAK and POPLAR trials. Ann. Oncol. 2020, 31, 525–531. [Google Scholar] [CrossRef] [Green Version]
- Hopkins, A.M.; Kichenadasse, G.; Karapetis, C.S.; Rowland, A.; Sorich, M.J. Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab. Clin. Cancer Res. 2020, 26, 5487–5493. [Google Scholar] [CrossRef]
- Hopkins, A.M.; Kichenadasse, G.; McKinnon, R.A.; Abuhelwa, A.Y.; Logan, J.M.; Badaoui, S.; Karapetis, C.S.; Rowland, A.; Sorich, M.J. Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: Post hoc analysis of IMpower150. Br. J. Cancer 2022, 126, 42–47. [Google Scholar] [CrossRef]
- Baek, Y.H.; Kang, E.J.; Hong, S.; Park, S.H.; Kim, J.H.; Shin, J.Y. Survival outcomes of patients with non-small cell lung cancer concomitantly receiving proton pump inhibitors and immune checkpoint inhibitors. Int. J. Cancer 2022, 150, 1291–1300. [Google Scholar] [CrossRef] [PubMed]
- Buti, S.; Bersanelli, M.; Perrone, F.; Bracarda, S.; Di Maio, M.; Giusti, R.; Nigro, O.; Cortinovis, D.L.; Aerts, J.; Guaitoli, G.; et al. Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. Eur. J. Cancer 2021, 150, 224–231. [Google Scholar] [CrossRef] [PubMed]
- Qin, B.D.; Jiao, X.D.; Zhou, X.C.; Shi, B.; Wang, J.; Liu, K.; Wu, Y.; Ling, Y.; Zang, Y.S. Effects of concomitant proton pump inhibitor use on immune checkpoint inhibitor efficacy among patients with advanced cancer. Oncoimmunology 2021, 10, 1929727. [Google Scholar] [CrossRef] [PubMed]
- Kostine, M.; Mauric, E.; Tison, A.; Barnetche, T.; Barre, A.; Nikolski, M.; Rouxel, L.; Dutriaux, C.; Dousset, L.; Prey, S.; et al. Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events. Eur. J. Cancer 2021, 157, 474–484. [Google Scholar] [CrossRef]
- Suzuki, K.; Doki, K.; Homma, M.; Tamaki, H.; Hori, S.; Ohtani, H.; Sawada, Y.; Kohda, Y. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br. J. Clin. Pharmacol. 2009, 67, 44–49. [Google Scholar] [CrossRef] [Green Version]
- Chu, M.P.; Hecht, J.R.; Slamon, D.; Wainberg, Z.A.; Bang, Y.J.; Hoff, P.M.; Sobrero, A.; Qin, S.; Afenjar, K.; Houe, V.; et al. Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial. JAMA Oncol. 2017, 3, 767–773. [Google Scholar] [CrossRef]
- Wong, G.G.; Ha, V.; Chu, M.P.; Dersch-Mills, D.; Ghosh, S.; Chambers, C.R.; Sawyer, M.B. Effects of Proton Pump Inhibitors on FOLFOX and CapeOx Regimens in Colorectal Cancer. Clin. Colorectal Cancer. 2019, 18, 72–79. [Google Scholar] [CrossRef]
- Kichenadasse, G.; Miners, J.O.; Mangoni, A.A.; Karapetis, C.S.; Hopkins, A.M.; Sorich, M.J. Proton Pump Inhibitors and Survival in Patients With Colorectal Cancer Receiving Fluoropyrimidine-Based Chemotherapy. J. Natl. Compr. Cancer Netw. 2021, 19, 1037–1044. [Google Scholar] [CrossRef]
- Pouya, F.D.; Rasmi, Y.; Camci, I.Y.; Tutar, Y.; Nemati, M. Performance of capecitabine in novel combination therapies in colorectal cancer. J. Chemother. 2021, 33, 375–389. [Google Scholar] [CrossRef]
- Peng, K.; Chen, K.; Teply, B.A.; Yee, G.C.; Farazi, P.A.; Lyden, E.R. Impact of Proton Pump Inhibitor Use on the Effectiveness of Immune Checkpoint Inhibitors in Advanced Cancer Patients. Ann. Pharmacother. 2021, 10600280211033938. [Google Scholar] [CrossRef]
- Li, C.; Xia, Z.; Li, A.; Meng, J. The effect of proton pump inhibitor uses on outcomes for cancer patients treated with immune checkpoint inhibitors: A meta-analysis. Ann. Transl. Med. 2020, 8, 1655. [Google Scholar] [CrossRef] [PubMed]
- Mollica, V.; Santoni, M.; Matrana, M.R.; Basso, U.; De Giorgi, U.; Rizzo, A.; Maruzzo, M.; Marchetti, A.; Rosellini, M.; Bleve, S.; et al. Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma. Target. Oncol. 2022, 17, 61–68. [Google Scholar] [CrossRef] [PubMed]
- Farrell, B.; Pottie, K.; Thompson, W.; Boghossian, T.; Pizzola, L.; Rashid, F.J.; Rojas-Fernandez, C.; Walsh, K.; Welch, V.; Moayyedi, P. Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline. Can. Fam. Physician 2017, 63, 354–364. [Google Scholar]
- van Leeuwen, R.W.; Peric, R.; Hussaarts, K.G.; Kienhuis, E.; IJzerman, N.S.; de Bruijn, P.; van der Leest, C.; Codrington, H.; Kloovert, J.S.; van der Holt, B.; et al. Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients with Non-Small-Cell Lung Cancer. J. Clin. Oncol. 2016, 34, 1309–1314. [Google Scholar] [CrossRef]
Drug Name: | PK Interactions [31,46] | Recommendations [31,46] | Clinical Impact |
---|---|---|---|
Afatinib | NA | NA | NA |
Alectinib | ± | NA | NA |
Axitinib | + | H2A: OK, PPI: OK | |
Cabozantinib | ± | H2A: OK, PPI: OK | |
Crizotinib | 0 | H2A: OK, PPI: OK | |
Dasatinib | ++ | H2A: OK, PPI: no | NA |
Erlotinib | ++ | H2A: OK, PPI: no | YES [38,39,40] |
Gefitinib | +++ | H2A: no, PPI: no | YES [38,39,40] |
Imatinib | 0 | H2A: OK, PPI: OK | |
Lapatinib | + | H2A: no, PPI: no | |
Lenvatinib | 0 | H2A: OK, PPI: OK | |
Nilotinib | + | H2A: OK, PPI: OK | |
Osimertinib | 0 | H2A: OK, PPI: OK | |
Pazopanib | ++ | H2A: OK, PPI: OK | YES [44] |
Regorafenib | 0 [47] | H2A: OK, PPI: OK | |
Sorafenib | 0 | H2A: OK, PPI: OK | Conflicting results [48,49,50] |
Sunitinib | + | H2A: OK, PPI: OK | Conflicting results [40,41,42] |
Vandetanib | + | H2A: OK, PPI: OK |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Raoul, J.-L.; Edeline, J.; Simmet, V.; Moreau-Bachelard, C.; Gilabert, M.; Frénel, J.-S. Long-Term Use of Proton Pump Inhibitors in Cancer Patients: An Opinion Paper. Cancers 2022, 14, 1156. https://doi.org/10.3390/cancers14051156
Raoul J-L, Edeline J, Simmet V, Moreau-Bachelard C, Gilabert M, Frénel J-S. Long-Term Use of Proton Pump Inhibitors in Cancer Patients: An Opinion Paper. Cancers. 2022; 14(5):1156. https://doi.org/10.3390/cancers14051156
Chicago/Turabian StyleRaoul, Jean-Luc, Julien Edeline, Victor Simmet, Camille Moreau-Bachelard, Marine Gilabert, and Jean-Sébastien Frénel. 2022. "Long-Term Use of Proton Pump Inhibitors in Cancer Patients: An Opinion Paper" Cancers 14, no. 5: 1156. https://doi.org/10.3390/cancers14051156